The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
<h4>Purpose</h4>To evaluate the prognostic value of pretreatment 18F-FDG PET/CT after consolidation therapy of 131I-rituximab in patients with diffuse large B-cell lymphoma (DLBCL) who had acquired complete remission after receiving chemotherapy.<h4>Methods</h4>Patients who w...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0273839 |
| _version_ | 1828172875746508800 |
|---|---|
| author | Joon Ho Choi Ilhan Lim Byung Hyun Byun Byung Il Kim Chang Woon Choi Hye Jin Kang Dong-Yeop Shin Sang Moo Lim |
| author_facet | Joon Ho Choi Ilhan Lim Byung Hyun Byun Byung Il Kim Chang Woon Choi Hye Jin Kang Dong-Yeop Shin Sang Moo Lim |
| author_sort | Joon Ho Choi |
| collection | DOAJ |
| description | <h4>Purpose</h4>To evaluate the prognostic value of pretreatment 18F-FDG PET/CT after consolidation therapy of 131I-rituximab in patients with diffuse large B-cell lymphoma (DLBCL) who had acquired complete remission after receiving chemotherapy.<h4>Methods</h4>Patients who were diagnosed with DLBCL via histologic confirmation were retrospectively reviewed. All patients had achieved complete remission after 6 to 8 cycles of R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) chemotherapy after which they underwent consolidation treatment with 131I-rituximab. 18F-FDG PET/CT scans were performed before R-CHOP for initial staging. The largest diameter of tumor, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained from pretreatment 18F-FDG PET/CT scans. Receiver-operating characteristic curves analysis was introduced for assessing the optimal criteria. Kaplan-Meier curve survival analysis was performed to evaluate both relapse free survival (RFS) and overall survival (OS).<h4>Results</h4>A total of 15 patients (12 males and 3 females) with a mean age of 56 (range, 30-73) years were enrolled. The median follow-up period of these patients was 73 months (range, 11-108 months). Four (27%) patients relapsed. Of them, three died during follow-up. Median values of the largest tumor size, highest SUVmax, MTV, and TLG were 5.3 cm (range, 2.0-16.4 cm), 20.2 (range, 11.1-67.4), 231.51 (range, 15-38.34), and 1277.95 (range, 238.37-10341.04), respectively. Patients with SUVmax less than or equal to 16.9 showed significantly worse RFS than patients with SUVmax greater than 16.9 (5-year RFS rate: 60% vs. 100%, p = 0.008). Patients with SUVmax less than or equal to 16.9 showed significantly worse OS than patients with SUVmax greater than 16.9 (5-year OS rate: 80% vs. 100% p = 0.042).<h4>Conclusion</h4>Higher SUVmax at pretreatment 18F-FDG PET/CT was associated with better relapse free survival and overall survival in DLBCL patients after consolidation therapy with 131I-rituximab. However, because this study has a small number of patients, a phase 3 study with a larger number of patients is needed for clinical application in the future. |
| first_indexed | 2024-04-12T03:48:04Z |
| format | Article |
| id | doaj.art-de9a954789bc44edb13dd33f505b238d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T03:48:04Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-de9a954789bc44edb13dd33f505b238d2022-12-22T03:49:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01179e027383910.1371/journal.pone.0273839The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.Joon Ho ChoiIlhan LimByung Hyun ByunByung Il KimChang Woon ChoiHye Jin KangDong-Yeop ShinSang Moo Lim<h4>Purpose</h4>To evaluate the prognostic value of pretreatment 18F-FDG PET/CT after consolidation therapy of 131I-rituximab in patients with diffuse large B-cell lymphoma (DLBCL) who had acquired complete remission after receiving chemotherapy.<h4>Methods</h4>Patients who were diagnosed with DLBCL via histologic confirmation were retrospectively reviewed. All patients had achieved complete remission after 6 to 8 cycles of R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone) chemotherapy after which they underwent consolidation treatment with 131I-rituximab. 18F-FDG PET/CT scans were performed before R-CHOP for initial staging. The largest diameter of tumor, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained from pretreatment 18F-FDG PET/CT scans. Receiver-operating characteristic curves analysis was introduced for assessing the optimal criteria. Kaplan-Meier curve survival analysis was performed to evaluate both relapse free survival (RFS) and overall survival (OS).<h4>Results</h4>A total of 15 patients (12 males and 3 females) with a mean age of 56 (range, 30-73) years were enrolled. The median follow-up period of these patients was 73 months (range, 11-108 months). Four (27%) patients relapsed. Of them, three died during follow-up. Median values of the largest tumor size, highest SUVmax, MTV, and TLG were 5.3 cm (range, 2.0-16.4 cm), 20.2 (range, 11.1-67.4), 231.51 (range, 15-38.34), and 1277.95 (range, 238.37-10341.04), respectively. Patients with SUVmax less than or equal to 16.9 showed significantly worse RFS than patients with SUVmax greater than 16.9 (5-year RFS rate: 60% vs. 100%, p = 0.008). Patients with SUVmax less than or equal to 16.9 showed significantly worse OS than patients with SUVmax greater than 16.9 (5-year OS rate: 80% vs. 100% p = 0.042).<h4>Conclusion</h4>Higher SUVmax at pretreatment 18F-FDG PET/CT was associated with better relapse free survival and overall survival in DLBCL patients after consolidation therapy with 131I-rituximab. However, because this study has a small number of patients, a phase 3 study with a larger number of patients is needed for clinical application in the future.https://doi.org/10.1371/journal.pone.0273839 |
| spellingShingle | Joon Ho Choi Ilhan Lim Byung Hyun Byun Byung Il Kim Chang Woon Choi Hye Jin Kang Dong-Yeop Shin Sang Moo Lim The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. PLoS ONE |
| title | The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. |
| title_full | The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. |
| title_fullStr | The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. |
| title_full_unstemmed | The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. |
| title_short | The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy. |
| title_sort | role of 18f fdg pet ct in patients with diffuse large b cell lymphoma after radioimmunotherapy using 131i rituximab as consolidation therapy |
| url | https://doi.org/10.1371/journal.pone.0273839 |
| work_keys_str_mv | AT joonhochoi theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT ilhanlim theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT byunghyunbyun theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT byungilkim theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT changwoonchoi theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT hyejinkang theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT dongyeopshin theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT sangmoolim theroleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT joonhochoi roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT ilhanlim roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT byunghyunbyun roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT byungilkim roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT changwoonchoi roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT hyejinkang roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT dongyeopshin roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy AT sangmoolim roleof18ffdgpetctinpatientswithdiffuselargebcelllymphomaafterradioimmunotherapyusing131irituximabasconsolidationtherapy |